Department of Digestive and Hepatobiliary/Pancreatic Surgery, Groeninge Hospital, President Kennedylaan 4, 8500, Kortrijk, Belgium.
Department of Pathological Anatomy, Groeninge Hospital, Kortrijk, Belgium.
Langenbecks Arch Surg. 2022 Sep;407(6):2399-2414. doi: 10.1007/s00423-022-02534-4. Epub 2022 May 2.
Laparoscopic liver resection (LLR) has gained acceptance as an effective treatment for colorectal liver metastases (CRLM) in selected patients, providing similar oncologic outcomes compared to open liver resection (OLR). The aim of this study was to determine prognostic factors for survival outcomes associated with LLR for CRLM.
A single-center retrospective analysis of a prospectively maintained database was performed. The inclusion period ranged from September 2011 until mid-March 2020.
Two hundred consecutive LLRs were included. The 5-year overall survival (OS) and disease-free survival (DFS) rates equalled 54.8% and 49%, respectively. A pushing (HR = 5.42, 95% CI 1.56-18.88, p = 0.008), as well as a replacement (3.87, 1.05-14.2, p = 0.04) growth pattern of the CRLM, poor differentiation of the primary colorectal cancer (CRC) (3.72, 1.72-8.07, p < 0.001) and administration of neoadjuvant chemotherapy (NAC) (2.95, 1.28-6.8, p = 0.01) were identified as independent predictors of a worse OS. Requirement of more than 6 cycles of NAC (6.17, 2.37-16.03, p < 0.001), a replacement (4.96, 1.91-12.87, p < 0.001), as well as a pushing (4.3, 1.68-11, p = 0.002) growth pattern of the CRLM and poor differentiation of the primary CRC (2.61, 1.31-5.2, p = 0.006) were identified as independent predictors of a worse DFS.
LLR for CRLM offers adequate long-term oncologic outcomes. OS and DFS rates are negatively affected by the administration of NAC and by pathological features, including the differentiation grade of the primary CRC and the histological growth pattern of the CRLM.
腹腔镜肝切除术(LLR)已被接受为治疗结直肠癌肝转移(CRLM)的有效方法,在选择的患者中,其与开腹肝切除术(OLR)相比具有相似的肿瘤学结果。本研究的目的是确定与 LLR 治疗 CRLM 相关的生存结果的预后因素。
对前瞻性维护的数据库进行单中心回顾性分析。纳入期为 2011 年 9 月至 2020 年 3 月中旬。
共纳入 200 例连续接受 LLR 的患者。5 年总生存率(OS)和无病生存率(DFS)分别为 54.8%和 49%。CRLM 的推挤(HR=5.42,95%CI 1.56-18.88,p=0.008)和替代(3.87,1.05-14.2,p=0.04)生长模式、原发性结直肠癌(CRC)的分化不良(3.72,1.72-8.07,p<0.001)和新辅助化疗(NAC)的应用(2.95,1.28-6.8,p=0.01)被确定为 OS 较差的独立预测因素。需要超过 6 个周期的 NAC(6.17,2.37-16.03,p<0.001)、替代(4.96,1.91-12.87,p<0.001)和推挤(4.3,1.68-11,p=0.002)生长模式以及原发性 CRC 的分化不良(2.61,1.31-5.2,p=0.006)被确定为 DFS 较差的独立预测因素。
CRLM 的 LLR 提供了足够的长期肿瘤学结果。OS 和 DFS 率受到 NAC 的应用和病理特征的负面影响,包括原发性 CRC 的分化程度和 CRLM 的组织学生长模式。